Bioasis Technologies Inc (CVE:BTI) (OTCQB:BIOAF) announced Tuesday that the US Patent and Trademark Office (USPTO) issued a patent for the company’s xB3 platform technology, which is designed to deliver therapeutics across the blood-brain barrier (BBB).
The xB3 method utilizes Bioasis’ novel platform technology to administer a broad array of therapeutic agents to the brain tissue in patients who can benefit from this targeted delivery, the company said, such as those with lysosomal storage diseases.
“We are excited about the issuance of this patent by the US Patent Office because it represents a major milestone for our intellectual property protection around our core assets,” CEO Deborah Rathjen said in a statement. “Adding to the already granted patents in the U.S. and around the world, this further strengthens and reinforces our standing around our core technology and our xB3 programs.”
READ: Bioasis on a roll after Chiesi validates the power of its technology to propel drugs across the blood-brain barrier
The blood-brain barrier plays an indispensable role in protecting the brain from blood-borne disease. However, it also blocks crucial medicines from reaching the brain posing an epic challenge to treating neurological diseases.
Like a key designed to open a lock, the xB3 platform unlocks the door to the blood-brain barrier, allowing compounds into the brain. In a nutshell, the xB3 platform uses a small peptide to ferry molecules across the BBB in a process called receptor-mediated transcytosis.
Contact Andrew Kessel at firstname.lastname@example.org
Follow him on Twitter @andrew_kessel